{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00025350", "CSN": null, "TRF": "ORD_1521384_01", "MRN": "40164203 (PF22139)", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1237264", "clinicalId": "1238634", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1521384_01", "SampleName": "US1456453.01", "Version": "0", "Sample": {"FM_Id": "ORD_1521384_01", "SampleId": "US1456453.01", "BlockId": "S111-46660F", "TRFNumber": "ORD_1521384_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_12_09", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "40", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M111-10036", "MRN": "40164203", "FullName": "\u912d\u4e00\u5fc3", "FirstName": "Yi Hsin", "LastName": "Cheng", "SubmittedDiagnosis": "Renal cell carcinoma", "Gender": "Male", "DOB": "1964_03_07", "OrderingMD": "\u6797\u5b50\u5e73", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Kidney", "CollDate": "2022_11_11", "ReceivedDate": "2022-12-21 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Renal Cell Carcinoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "13", "clinicalTrialCount": "18", "resistiveCount": "0", "sensitizingCount": "5"}, "VariantProperties": {"VariantProperty": [{"geneName": "BRCA2", "isVUS": "true", "variantName": "L1829F"}, {"geneName": "CARD11", "isVUS": "true", "variantName": "A687V"}, {"geneName": "IKBKE", "isVUS": "true", "variantName": "G660E"}, {"geneName": "MST1R", "isVUS": "true", "variantName": "V670G"}, {"geneName": "MYC", "isVUS": "true", "variantName": "K172Q"}, {"geneName": "ROS1", "isVUS": "true", "variantName": "D2213E,Y1353S"}, {"geneName": "SOCS1", "isVUS": "true", "variantName": "T57I"}, {"geneName": "TET2", "isVUS": "true", "variantName": "P555L"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "PBRM1", "Include": "true", "Alterations": {"Alteration": {"Name": "E1364*", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "15.8", "isEquivocal": "false", "name": "E1364*"}}, "Interpretation": "PBRM1 (Polybromo_1), also known as BAF180, encodes a subunit of ATP_dependent chromatin_remodeling complexes and a required cofactor for ligand_dependent transactivation by nuclear hormone receptors (Lemon et al., 2001; 11780067). Mutation, loss, or inactivation of PBRM1 has been reported in several cancers, suggesting PBRM1 is a tumor suppressor (Varela et al., 2011; 21248752, Jiao et al., 2013; 24185509, Xia et al., 2008; 18339845). Alterations such as seen here may disrupt PBRM1 function or expression (Hopson and Thompson, 2017; 28921948, Porter et al., 2017; 28053089, Niimi et al., 2015; 26117423, Brownlee et al., 2014; 24613357, Kakarougkas et al., 2014; 25066234, Gao et al., 2017; 28082722). Somatic mutations in PBRM1 are common in clear cell renal cell carcinomas (ccRCC) (41%) (Varela et al., 2011; 21248752). The PBRM1/ARID1A/SMARCA4 network of SWI/SNF chromatin remodeling complex components is a frequently mutated subnetwork of genes that may define a molecular subtype of ccRCC (Cancer Genome Atlas Research Network., 2013; 23792563). A case study reported loss of Brg1 expression in a rhabdoid RCC that may have arisen from a ccRCC (Rao et al., 2014; 24817979). Preclinical studies have shown that loss of PBRM1 increases the proliferation of ccRCC cell lines (Varela et al., 2011; 21248752). PBRM1 protein loss or mutation is correlated with late tumor stage, low differentiation grade, and/or poor patient prognosis in ccRCC (da Costa et al., 2014; 24053427, Paw\u0142owski et al., 2013; 22949125, Hakimi et al., 2013; 23036577); however, one ccRCC study reported no correlation between PBRM1 mutation and cancer_specific survival (Hakimi et al., 2013; 23620406). In ccRCC, PBRM1 alterations are generally observed to be mutually exclusive with BAP1 alterations (Varela et al., 2011; 21248752, Pena_Llopis et al., 2012; 22683710); a retrospective analysis of 145 primary ccRCCs found a decreased median overall survival for patients with mutations in both BAP1 and PBRM1 compared with patients having either mutated gene alone (Kapur et al., 2013; 23333114). On the basis of significant clinical data from prospective studies, PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors, such as nivolumab, pembrolizumab, cemiplimab, or dostarlimab, for patients with clear cell renal cell carcinoma (ccRCC) and prior anti_angiogenic therapy (Braun et al., 2019; 31486842, Braun et al., 2020; 32472114, Vano et al., 2020; ASCO GU Abstract 618, Miao et al., 2018; 29301960). Post hoc analysis of the Phase 3 CheckMate 025 study for metastatic ccRCC with progression on anti_angiogenics demonstrated improved median PFS (5.6 vs. 2.9 months, HR=0.67) and OS (27.9 vs. 20.9 months, HR=0.65) with nivolumab for patients harboring PBRM1 inactivating mutations (Braun et al., 2019; 31486842). Similarly, the Phase 2 real_world NIVOREN study reported improved nivolumab 1_year OS rates (84% vs. 74%, HR=0.59) for previously treated patients with ccRCC and PBRM1 protein loss by immunohistochemistry (Vano et al., 2020; ASCO GU Abstract 618). Although patients with PBRM1_mutated ccRCC have also benefited from nivolumab in combination with the anti_CTLA_4 immunotherapy ipilimumab or from the anti_PD_L1 immunotherapy atezolizumab (Miao et al., 2018; 29301960, Dizman et al., 2020; 32661119), PBRM1 mutation status was not associated with survival outcomes for combination nivolumab and ipilimumab in the Phase 3 CheckMate 214 study (Motzer et al., 2020; ASCO Abstract 5009) or for single_agent atezolizumab in the Phase 2 IMmotion150 study (McDermott et al., 2018; 29867230, Liu et al., 2020; 32358509) for treatment_naive advanced or metastatic ccRCC.", "Include": "true", "ClinicalTrialNote": "PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Pembrolizumab", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Pembrolizumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved for patients with tumor mutational burden (TMB)_high (\u226510 Muts/Mb), microsatellite instability_high (MSI_H), or mismatch repair_deficient (dMMR) solid tumors; as monotherapy for PD_L1_positive non_small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), cervical cancer, or esophageal cancer; and in combination with chemotherapy for PD_L1_positive triple_negative breast cancer (TNBC) or cervical cancer. It is also approved in various treatment settings as monotherapy for patients with melanoma, HNSCC, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma, endometrial carcinoma that is MSI_H or dMMR, classical Hodgkin lymphoma, or primary mediastinal large B_cell lymphoma; and in combination with chemotherapy or targeted therapy for NSCLC, HNSCC, esophageal or gastroesophageal junction cancer, renal cell carcinoma, TNBC, or endometrial carcinoma that is not MSI_H or dMMR. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of significant clinical evidence, PBRM1 inactivation may predict benefit from PD_1_targeting immunotherapies, such as nivolumab, pembrolizumab, cemiplimab, or dostarlimab, in patients with clear cell renal cell carcinoma and progression on prior anti_angiogenic therapy (Braun et al., 2019; 31486842, Braun et al., 2020; 32472114, Vano et al., 2020; ASCO GU Abstract 618, Miao et al., 2018; 29301960). </p> <p><b>Supporting Data:</b> In the KEYNOTE_427 Phase 2 study, first_line pembrolizumab elicited a 36% ORR, 58% DCR, and 7.1_month median PFS (mPFS) for patients with advanced clear cell renal cell carcinoma (ccRCC) and a 27% ORR, 43% DCR, and 4.2_month mPFS for patients with advanced non_clear cell RCC. Anti_tumor activity was seen for favorable_ and intermediate_ and/or poor_risk groups, PD_L1_positive and _negative groups, and patients with sarcomatoid histology (McDermott et al., 2021; 33529051, McDermott et al., 2021; 33529058). In the adjuvant setting for treatment_naive ccRCC, single_agent pembrolizumab improved disease_free survival compared with placebo (HR=0.68) in interim analysis of KEYNOTE_564 (Choueiri et al., 2021; 34407342). In Phase 3 studies, the combination of pembrolizumab with multi_TKIs such as lenvatinib or axitinib has significantly improved outcomes for patients with previously untreated ccRCC as compared with sunitinib monotherapy; CLEAR demonstrated an ORR of 71% vs 36% and improved mPFS (23.3 vs. 9.2 months, HR=0.42) and median OS (mOS; not reached for either arm, HR=0.72) for pembrolizumab plus lenvatinib (Motzer et al., 2021; 33616314, Porta et al., 2022; ESMO Abstract 1449MO), and KEYNOTE_426 showed improved mPFS (15.4 vs. 11.1 months, HR=0.71) and mOS (not reached vs. 35.7 months, HR=0.68) for pembrolizumab plus axitinib (Powles et al., 2020; 33284113, Rini et al., 2019; 30779529). The KEYNOTE_146 Phase 1b/2 study of lenvatinib combined with pembrolizumab also demonstrated an ORR of 77% (17/22) for treatment_naive patients with metastatic RCC compared with 41% (7/17) for patients previously treated with non_immune checkpoint inhibitor (ICI) therapies and 56% (58/104) for patients who had relapsed on prior treatment with an ICI (Lee et al., 2021; 34143969). For patients with non_clear cell RCC, the Phase 2 KEYNOTE_B61 study of frontline pembrolizumab plus lenvatinib preliminarily reported an ORR of 48% (39/82) and a DCR of 79% (65/82)(Albiges et al., 2022; ESMO Abstract 1448O). Although anti_tumor activity was also reported for frontline pembrolizumab with the multi_TKI pazopanib in a Phase 1/2 trial for advanced ccRCC, due to significant hepatotoxicity the combination was not recommended for further clinical investigation (Chowdhury et al., 2021; 34006498). Early phase trials have reported activity of pembrolizumab in combination with the CTLA_4_targeting immune checkpoint inhibitor ipilimumab, pegylated interferon alfa 2b, or the IL_10_targeting monoclonal antibody pegilodecakin in previously treated RCC (Atkins et al., 2018; 29358500, Tannir et al., 2021; 33709428, Naing et al., 2019; 31563517). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Cemiplimab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Cemiplimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC), cutaneous squamous cell carcinoma, or basal cell carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of significant clinical evidence, PBRM1 inactivation may predict benefit from PD_1_targeting immunotherapies, such as nivolumab, pembrolizumab, cemiplimab, or dostarlimab, in patients with clear cell renal cell carcinoma and progression on prior anti_angiogenic therapy (Braun et al., 2019; 31486842, Braun et al., 2020; 32472114, Vano et al., 2020; ASCO GU Abstract 618, Miao et al., 2018; 29301960). </p> <p><b>Supporting Data:</b> A Phase 1b trial evaluating combination cemiplimab with an oncolytic vaccinia virus for patients with metastatic or unresectable clear cell RCC observed 1 CR, 5 PRs, and reduction of tumor burden in 75% (12/16) of patients (Rha et al., 2020; AACR Abstract CT121). Cemiplimab has been studied primarily in advanced cutaneous squamous cell carcinoma (CSCC), where it elicited a combined ORR of 48% (41/85) in Phase 1 and 2 studies (Migden et al., 2018; 29863979). A Phase 2 trial of cemiplimab in patients with basal cell carcinoma (BCC) reported ORRs of 31% (5 CRs and 21 PRs) in patients with locally advanced BCC and 21% (6 PRs) in patients with metastatic BCC (Stratigos et al., 2020; EMSO Abstract LBA47, Lewis et al. 2020; doi: 10.1136/jitc_2020_SITC2020.0428). The Phase 3 EMPOWER_Lung 1 trial for advanced non_small cell lung cancer (NSCLC) with PD_L1 expression \u226550% reported that cemiplimab is associated with improved PFS (8.2 vs. 5.7 months), OS (not reached vs. 14.2 months), and ORR (37% vs. 21%) compared with chemotherapy (Sezer et al., 2020; ESMO Abstract LBA52). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Nivolumab", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response. It is FDA approved as a monotherapy in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, colorectal cancer (CRC), classical Hodgkin lymphoma (cHL), gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma or squamous cell carcinoma (ESCC). It is also approved in combination with chemotherapy to treat ESCC, in combination with cabozantinib to treat RCC, and in combination with relatlimab to treat melanoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of significant clinical evidence, PBRM1 inactivation may predict benefit from PD_1_targeting immunotherapies, such as nivolumab, pembrolizumab, cemiplimab, or dostarlimab, in patients with clear cell renal cell carcinoma and progression on prior anti_angiogenic therapy (Braun et al., 2019; 31486842, Braun et al., 2020; 32472114, Vano et al., 2020; ASCO GU Abstract 618, Miao et al., 2018; 29301960). </p> <p><b>Supporting Data:</b> Post hoc analysis of the Phase 3 CheckMate 025 study demonstrated improved ORR (39% vs. 22%), median PFS (5.6 vs. 2.9 months, HR=0.67), and median OS (27.9 vs. 20.9 months, HR=0.65) on treatment with nivolumab for patients with previously treated advanced clear cell renal cell carcinoma (ccRCC) harboring PBRM1 inactivating mutations compared with those with PBRM1_wildtype tumors (Braun et al., 2019; 31486842). Similarly, the Phase 2 real_world NIVOREN study reported improved 1_year OS rates on nivolumab (84% vs. 74%, HR=0.59) for previously treated ccRCC with PBRM1 protein loss by immunohistochemistry (Vano et al., 2020; ASCO GU Abstract 618). In the Phase 3 CheckMate 025 study for patients with advanced clear cell renal cell carcinoma (ccRCC) and previous antiangiogenic therapy, nivolumab monotherapy elicited improved median OS (mOS; 25.8 vs. 19.7 months, HR=0.73) and ORR (23% vs. 4%) compared with everolimus; baseline tumor PD_L1 expression was not associated with OS benefit (Motzer et al., 2020; 32673417, Motzer et al., 2015; 26406148). Single_agent nivolumab achieved a mOS of 21.8 months for previously treated ccRCC and 16.3 months for previously treated non_ccRCC in CheckMate 374 (McFarlane et al., 2020; 32641261, Vogelzang et al., 2020; 32718906). For treatment_naive patients with advanced ccRCC, the Phase 3 CheckMate 9ER study reported improved mOS (37.7 vs 34.3 months, HR=0.70), mPFS (16.6 vs. 8.3 months, HR=0.56), and ORR (56% vs. 28%, CR 12% vs 5.2%) for the combination of nivolumab and the multikinase inhibitor cabozantinib over sunitinib monotherapy (Motzer et al., 2022; 35688173), with benefit observed across risk status and PD_L1 expression subgroups (Choueiri et al., 2021; 33657295, Powles et al., 2022; ASCO GU Abstract 350). In a Phase 2 study, objective responses have been observed in treatment_naive patients with metastatic ccRCC treated with nivolumab or nivolumab in combination with ipilimumab (Vano et al., 2022; 35390339). Clinical benefit has also been reported from nivolumab in combination with other agents in Phase 1 trials, including sunitinib, pazopanib, axitinib, and bempegaldesleukin (Zibelman et al., 2019; ASCO Abstract 4567, Amin et al., 2018; 30348216, Diab et al., 2020; 32439653). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Dostarlimab", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Dostarlimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer or solid tumors. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of significant clinical evidence, PBRM1 inactivation may predict benefit from PD_1_targeting immunotherapies, such as nivolumab, pembrolizumab, cemiplimab, or dostarlimab, in patients with clear cell renal cell carcinoma and progression on prior anti_angiogenic therapy (Braun et al., 2019; 31486842, Braun et al., 2020; 32472114, Vano et al., 2020; ASCO GU Abstract 618, Miao et al., 2018; 29301960). </p> <p><b>Supporting Data:</b> The GARNET Phase 1 basket trial of dostarlimab in mismatch repair_deficient (dMMR) cancers included 1 patient with renal cell carcinoma who experienced an SD (Andre et al., 2021; ASCO GI Abstract 9). Dostarlimab has been studied primarily in recurrent and advanced mismatch repair_deficient (dMMR) endometrial and non_endometrial cancers (Andre et al., 2021; ASCO GI Abstract 9, Oaknin et al., 2020; 33001143, Berton et al., 2021; ASCO Abstract 2564). In the Phase 1 GARNET trial, single_agent dostarlimab elicited an ORR of 39% (41/106) and an immune_related ORR of 46% (50/110) for patients with non_endometrial dMMR solid tumors (Andre et al., 2021; ASCO GI Abstract 9, Andre et al., 2021; ESMO GI Abstract SO_9). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04237649", "Include": "true"}, {"nctId": "NCT04736706", "Include": "true"}, {"nctId": "NCT05166577", "Include": "true"}, {"nctId": "NCT04152018", "Include": "true"}, {"nctId": "NCT03530397", "Include": "true"}, {"nctId": "NCT04261439", "Include": "true"}, {"nctId": "NCT04047862", "Include": "true"}, {"nctId": "NCT05098847", "Include": "true"}, {"nctId": "NCT05102006", "Include": "true"}, {"nctId": "NCT03744468", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "VHL", "Include": "true", "Alterations": {"Alteration": {"Name": "S65fs*1", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "13.29", "isEquivocal": "false", "name": "S65fs*1"}}, "Interpretation": "VHL encodes the protein pVHL (von Hippel_Lindau tumor suppressor), which is frequently inactivated, either via mutation or hypermethylation, in clear cell renal cell carcinoma (ccRCC) and plays an important role in its pathogenesis (Li and Kaelin, 2011; 21763962). Inactivating mutations in VHL lead to dysregulation of critical downstream growth regulators, especially members of the HIF family and VEGF (Kaelin and Ratcliffe, 2008; 18498744, Gnarra et al., 1996; 8855222). Alterations such as seen here may disrupt VHL function or expression (Albers et al., 2013; 23606570, Asakawa et al., 2012; 22462637, Banks et al., 2006; 16488999, Bond et al., 2011; 21454469, Clifford et al., 2001; 11331613, Cockman et al., 2000; 10823831, Corn et al., 2003; 14556007, Dandanell et al., 2012; 22799452, Feldman et al., 1999; 10635329, Feldman et al., 2003; 14636579, Hansen et al., 2002; 11865071, Hoffman et al., 2001; 11331612, Khacho et al., 2008; 17967880, Kibel et al., 1995; 7660130, Knauth et al., 2006; 16261165, Lewis and Roberts., 2004; 14691445, Li et al., 2002; 11739384, Li et al., 2002; 12056827, Liu and Nussinov, 2009; 19798438, Losonczy et al., 2013; 23298237, Maher et al., 1996; 8730290, McClellan et al., 2005; 15935760, Metzger and Michaelis, 2009; 19073890, Miller et al., 2005; 15611064, Moore et al., 2011; 22022277, Neumann et al., 1995; 7563486, Ohh et al., 1999; 10587522, Ohh et al., 2000; 10878807, Olschwang et al., 1998; 9829912, Patocs et al., 2008; 18416845, Rechsteiner et al., 2011; 21715564, Richards, 2001; 14987375, Ritter et al., 1996; 8772572, Schoenfeld et al., 2000; 10900011, Shmueli et al., 2013; 23840444, Siu et al., 2011; 21362373, Weirich et al., 2002; 12414898, Zbar et al., 1996; 8956040, Zhou et al., 2004; 14973063, Shukiya et al., 2020; 32234874, Sun et al., 2020; 32513235). VHL mutations and VHL promoter methylation have been reported to occur frequently in renal carcinoma (RCC), particularly in clear cell renal carcinoma (ccRCC) (Bruder et al., 2004; 15316311, Dulaimi et al., 2004; 15217927, Fleming, 1997; 9156283), and are early events in RCC tumorigenesis (Gerlinger et al., 2014; 24487277, Sankin et al., 2014; 25124064). VHL mutations have been reported in 52% ccRCC, 4.3% of chromophobe RCC, and 2.0% of papillary RCC (COSMIC, Jan 2022) (Tate et al., 2019; 30371878). Studies exploring the prognostic value of VHL mutation in RCC have given mixed results (Cowey and Rathmell., 2009; 19216840). Various strategies are under clinical investigation to block pathways downstream of inactivated VHL, including HIF, VEGF, and mTOR. The multikinase inhibitor sunitinib, which has activity against VEGFRs and other targets, is approved to treat several tumor types and has shown strong efficacy in patients with VHL disease (Jimenez et al., 2009; 19017755, Kim et al., 2013; 24454008, Tsimafeyeu, 2015; 26881543, Babinska et al., 2015; 26812297, Kobayashi et al., 2016; 26984080). Several clinical trials found response rates up to 64% and DCRs up to 90% (Matin et al., 2010; ASCO Abstract 3040, Jonasch et al., 2011; 22105611, Roma et al., 2015; 25391617). However, multiple clinical studies of sunitinib in patients with renal cell carcinoma reported that mutation or inactivation of the VHL gene is not significantly associated with therapeutic response or survival (Saez et al., 2012; ASCO Abstract 4630, Rini et al., 2006; 16827904, Choueiri et al., 2008; 18635227, Motzeret al., 2014; 25100134). Other agents that inhibit VEGFRs, including the multikinase inhibitors sorafenib, axitinib, pazopanib, regorafenib, cabozantinib, and vandetanib; the anti_VEGFR2 antibody ramucirumab; and the mTOR inhibitors everolimus and temsirolimus, are also approved in multiple tumor types. However, studies have similarly shown that VHL mutation or inactivation does not correlate with responses to these agents (Hutson et al., 2008; ASCO Abstract 5046, Choueiri et al., 2008; 18635227, Cho et al., 2007; 17956710, Choueiri et al., 2013; 23881929). Therefore, it is unclear whether these therapeutic strategies would be beneficial in this case. The HIF2a inhibitor belzutifan achieved an ORR of 64% in a clinical trial for VHL disease_associated clear cell renal cell carcinoma (Srinivasan et al., 2022; ESMO Abstract LBA69). Responses were also seen in other VHL mutation_associated tumor types, including CNS hemangioblastomas and pancreatic neuroendocrine tumors; however, it was not determined whether VHL inactivation was significantly associated with these responses (Srinivasan et al., 2022; ESMO Abstract LBA69, Jonasch et al., 2021; 34818478). Inactivating VHL mutations are characteristic of the clear cell subtype of renal cell carcinoma (RCC) (NCCN Kidney Cancer Guidelines, v1.2023)(Escudier et al., 2019; 30788497, Moch et al., 2016; 26935559). Inactivating germline mutations in VHL underlie von Hippel_Lindau syndrome, a rare but highly penetrant autosomal dominant syndrome occurring in 1/36,000 live births that predisposes to the development of several types of cancer, including clear cell renal cell carcinomas and pancreatic neuroendocrine tumors, as well as retinal and central nervous system hemangioblastomas (Maher et al., 2011; 21386872, Haddad et al., 2013; 24138046, Richard et al., 2013; 22659535). In the appropriate clinical context, germline testing of VHL is recommended.", "Include": "true", "ClinicalTrialNote": "Clinical evidence suggests that inactivation of VHL may predict sensitivity to HIF2a inhibitors.", "Therapies": {"Therapy": {"Name": null, "GenericName": "Belzutifan", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Belzutifan is a HIF2a inhibitor. It is FDA approved to treat adult patients with von Hippel_Lindau (VHL)_associated renal cell carcinoma, central nervous system (CNS) hemangioblastomas, and pancreatic neuroendocrine tumors. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in von Hippel_Lindau (VHL) disease_associated renal cell carcinoma, hemangioblastoma, and pancreatic neuroendocrine tumors, VHL inactivation may predict sensitivity to the HIF2a inhibitor belzutifan (Srinivasan et al., 2021; ASCO Abstract 4555). </p> <p><b>Supporting Data:</b> A Phase 2 study of belzutifan for the treatment of clear cell renal cell carcinoma (RCC) achieved an ORR of 64% (39/61; 4 CRs, 35 PRs) (Srinivasan et al., 2022; ESMO Abstract LBA69) and a 24_month PFS of 96% (Jonasch et al., 2021; 34818478). A Phase 1/2 clinical trial of 55 patients with advanced clear cell RCC achieved an ORR of 25% (14 PRs), a DCR of 80%, and a median PFS of 15 months (Choueiri et al., 2021; 33888901, Choueiri et al., 2020; ASCO Abstract 611). In a Phase 2 study of belzutifan plus cabozantinib for patients with advanced clear cell RCC previously treated with immunotherapy, the ORR was 22% (9 PRs) with a DCR of 90% and a median PFS of 17 months; at the time of data cutoff, all responses were ongoing (McDermott et al., 2021; ESMO Abstract 656MO). In the cohort of this Phase 2 study that assessed treatment_naive patients with advanced clear cell RCC, belzutifan plus cabozantinib was associated with an ORR of 57% (2 CRs, 18 PRs), median PFS of 30.3 months, median DOR of 28.6 months, and estimated 12_month OS rate of 96% (Choueiri et al., 2022; ESMO Abstract 1447O). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04736706", "Include": "true"}, {"nctId": "NCT05030506", "Include": "true"}, {"nctId": "NCT04586231", "Include": "true"}, {"nctId": "NCT04626479", "Include": "true"}, {"nctId": "NCT04626518", "Include": "true"}, {"nctId": "NCT04895748", "Include": "true"}, {"nctId": "NCT03634540", "Include": "true"}, {"nctId": "NCT04627064", "Include": "true"}, {"nctId": "NCT04846920", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_high and MSI_low were each reported in 1% of cases in a study of 152 renal cell carcinomas (RCC) (Stoehr et al., 2012; 22378480). Another study reported that fewer than 1% of RCC cases had MSI_H status (Bratslavsky et al., 2021; 33775530). Published data investigating the prognostic implications of MSI in RCC are limited (PubMed, Jan 2022). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Kidney carcinoma, including renal clear cell carcinoma, renal papillary carcinoma, and renal sarcomatoid carcinoma subtypes, harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 0_2% of cases have been reported to harbor high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421, Pal et al., 2018; 28592388). Renal cell carcinomas harbor an average TMB among solid tumors, with a median of approximately 1_2 non_synonymous somatic mutations per megabase in kidney clear_cell or papillary carcinoma (Lawrence et al., 2013; 23770567, Alexandrov et al., 2013; 23945592). For patients with ccRCC, increased TMB is associated with poor survival outcomes, higher tumor grade, and advanced pathological stage (Zhang et al., 2019; 31930049). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "PBRM1", "Alteration": "E1364*", "Title": "KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "ADORA2A, CD73, PD_1", "Locations": "Taipei (Taiwan), Shatin, New Territories (Hong Kong), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Toronto (Canada), Missouri", "NCTID": "NCT04237649", "Note": "PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "PBRM1", "Alteration": "E1364*", "Title": "A Study of Pembrolizumab (MK_3475) in Combination With Belzutifan (MK_6482) and Lenvatinib (MK_7902), or Pembrolizumab/Quavonlimab (MK_1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK_6482_012)", "StudyPhase": "PHASE 3", "Target": "FGFRs, RET, PDGFRA, VEGFRs, KIT, CTLA_4, HIF2a, PD_1", "Locations": "Taipei (Taiwan), Taoyuan (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Wenzhou (China), Xiamen (China), Ningbo (China), Hangzhou (China), Jiaxing (China)", "NCTID": "NCT04736706", "Note": "PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "PBRM1", "Alteration": "E1364*", "Title": "Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM_NPC", "StudyPhase": "PHASE 1/2", "Target": "HDAC, PD_1", "Locations": "Taipei City (Taiwan), Taipei (Taiwan), Taoyuan City (Taiwan), Sha Tin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Kuching (Malaysia), Kuala Lumpur (Malaysia), Singapore (Singapore), Blacktown (Australia)", "NCTID": "NCT05166577", "Note": "PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "PBRM1", "Alteration": "E1364*", "Title": "Study of PF_06940434 in Patients With Advanced or Metastatic Solid Tumors.", "StudyPhase": "PHASE 1", "Target": "PD_1", "Locations": "Taipei (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Liverpool (Australia), Wollongong (Australia), Poprad (Slovakia), Bratislava (Slovakia), Washington, California, Arizona", "NCTID": "NCT04152018", "Note": "PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "PBRM1", "Alteration": "E1364*", "Title": "A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_L1, PD_1, CTLA_4", "Locations": "Taipei (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Cheongju_si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Melbourne (Australia), Amsterdam (Netherlands), Ravenna (Italy)", "NCTID": "NCT03530397", "Note": "PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "PBRM1", "Alteration": "E1364*", "Title": "A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab", "StudyPhase": "PHASE 1", "Target": "PD_1", "Locations": "Taipei (Taiwan), Chuo ku (Japan), Essen (Germany), Napoli (Italy), Barcelona (Spain), Madrid (Spain), California, Texas", "NCTID": "NCT04261439", "Note": "PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "PBRM1", "Alteration": "E1364*", "Title": "Study of BGB_A1217 in Combination With Tislelizumab in Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_1, TIGIT", "Locations": "Taipei (Taiwan), Taoyuan (Taiwan), Hualien City (Taiwan), Taichung (Taiwan), Fujian (China), Hangzhou (China), Shanghai (China), Guangdong (China), Changsha (China), Wuhan (China)", "NCTID": "NCT04047862", "Note": "PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "PBRM1", "Alteration": "E1364*", "Title": "Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors", "StudyPhase": "PHASE 2", "Target": "FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1", "Locations": "Shanghai (China)", "NCTID": "NCT05098847", "Note": "PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "PBRM1", "Alteration": "E1364*", "Title": "Phase Ib/II Clinical Study of LBL_007 in Treatment of Advanced Malignant Tumors", "StudyPhase": "PHASE 1/2", "Target": "LAG3, PD_1", "Locations": "Nanchang (China), Changzhou (China), Guangzhou (China), Changsha (China), Wuhan (China), Bengbu (China), Linyi (China), Zhengzhou (China), Jinan (China), Chongqing (China)", "NCTID": "NCT05102006", "Note": "PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "PBRM1", "Alteration": "E1364*", "Title": "Study of BGB_A425 in Combination With Tislelizumab in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PD_1, TIM_3", "Locations": "Busan (Korea, Republic of), Ulsan (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Perth (Australia), Hervey Bay (Australia), Birtinya (Australia), Adelaide (Australia), Melbourne (Australia)", "NCTID": "NCT03744468", "Note": "PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "VHL", "Alteration": "S65fs*1", "Title": "A Study of Pembrolizumab (MK_3475) in Combination With Belzutifan (MK_6482) and Lenvatinib (MK_7902), or Pembrolizumab/Quavonlimab (MK_1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK_6482_012)", "StudyPhase": "PHASE 3", "Target": "FGFRs, RET, PDGFRA, VEGFRs, KIT, CTLA_4, HIF2a, PD_1", "Locations": "Taipei (Taiwan), Taoyuan (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Wenzhou (China), Xiamen (China), Ningbo (China), Hangzhou (China), Jiaxing (China)", "NCTID": "NCT04736706", "Note": "Clinical evidence suggests that inactivation of VHL may predict sensitivity to HIF2a inhibitors.", "Include": "true"}, {"Gene": "VHL", "Alteration": "S65fs*1", "Title": "A Study of Belzutifan (MK_6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK_7902) With or Without Pembrolizumab (MK_3475) in China Participants With Advanced Renal Cell Carcinoma (MK_6482_010)", "StudyPhase": "PHASE 1", "Target": "FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1, HIF2a", "Locations": "Hangzhou (China), Nanjing (China), Guangzhou (China), Tianjin (China), Beijing (China)", "NCTID": "NCT05030506", "Note": "Clinical evidence suggests that inactivation of VHL may predict sensitivity to HIF2a inhibitors.", "Include": "true"}, {"Gene": "VHL", "Alteration": "S65fs*1", "Title": "A Study of MK_6482 in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK_6482_011)", "StudyPhase": "PHASE 3", "Target": "HIF2a, MET, ROS1, RET, VEGFRs, FGFRs, PDGFRA, KIT", "Locations": "Hwasun (Korea, Republic of), Fukuoka (Japan), Seoul (Korea, Republic of), Osakasayama (Japan), Suita (Japan), Kashihara (Japan), Toyoake (Japan), Hamamatsu (Japan), Yokohama (Japan), Tokyo (Japan)", "NCTID": "NCT04586231", "Note": "Clinical evidence suggests that inactivation of VHL may predict sensitivity to HIF2a inhibitors.", "Include": "true"}, {"Gene": "VHL", "Alteration": "S65fs*1", "Title": "Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK_3475_03A)", "StudyPhase": "PHASE 1/2", "Target": "PD_1, HIF2a, LAG_3, FGFRs, RET, PDGFRA, VEGFRs, KIT", "Locations": "Songpagu (Korea, Republic of), Seoul (Korea, Republic of), Herston (Australia), Blacktown (Australia), Kogarah (Australia), Heidelberg (Australia), Haifa (Israel), Jerusalem (Israel), Petah Tiqwa (Israel), Ramat Gan (Israel)", "NCTID": "NCT04626479", "Note": "Clinical evidence suggests that inactivation of VHL may predict sensitivity to HIF2a inhibitors.", "Include": "true"}, {"Gene": "VHL", "Alteration": "S65fs*1", "Title": "Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK_3475_03B)", "StudyPhase": "PHASE 1/2", "Target": "HIF2a, CTLA_4, FGFRs, RET, PDGFRA, VEGFRs, KIT, ITL4, LAG_3, PD_1", "Locations": "Seoul (Korea, Republic of), Songpagu (Korea, Republic of), Herston (Australia), Blacktown (Australia), Kogarah (Australia), Melbourne (Australia), Jerusalem (Israel), Petah Tiqwa (Israel), Ramat Gan (Israel), Tel Aviv (Israel)", "NCTID": "NCT04626518", "Note": "Clinical evidence suggests that inactivation of VHL may predict sensitivity to HIF2a inhibitors.", "Include": "true"}, {"Gene": "VHL", "Alteration": "S65fs*1", "Title": "DFF332 as a Single Agent and in Combination With Everolimus & Immuno_Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies", "StudyPhase": "PHASE 1", "Target": "mTOR, HIF2a, ADORA2A, PD_1", "Locations": "Koto ku (Japan), Singapore (Singapore), Brno (Czechia), Milano (Italy), Villejuif Cedex (France), Barcelona (Spain), California, Missouri, Massachusetts, New York", "NCTID": "NCT04895748", "Note": "Clinical evidence suggests that inactivation of VHL may predict sensitivity to HIF2a inhibitors.", "Include": "true"}, {"Gene": "VHL", "Alteration": "S65fs*1", "Title": "A Trial of PT2977 in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC)", "StudyPhase": "PHASE 2", "Target": "MET, ROS1, RET, VEGFRs, HIF2a", "Locations": "Washington, California, Michigan, Massachusetts, Tennessee, Florida", "NCTID": "NCT03634540", "Note": "Clinical evidence suggests that inactivation of VHL may predict sensitivity to HIF2a inhibitors.", "Include": "true"}, {"Gene": "VHL", "Alteration": "S65fs*1", "Title": "ABEMA Alone or in COMBO With MK_6482", "StudyPhase": "PHASE 1", "Target": "CDK4, CDK6, HIF2a", "Locations": "Massachusetts", "NCTID": "NCT04627064", "Note": "Clinical evidence suggests that inactivation of VHL may predict sensitivity to HIF2a inhibitors.", "Include": "true"}, {"Gene": "VHL", "Alteration": "S65fs*1", "Title": "A Study of Belzutifan (MK_6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK_6482_018)", "StudyPhase": "PHASE 1", "Target": "HIF2a", "Locations": "Michigan, Massachusetts, Tennessee, Texas", "NCTID": "NCT04846920", "Note": "Clinical evidence suggests that inactivation of VHL may predict sensitivity to HIF2a inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21763962", "FullCitation": "Li L, et al. Hematol. Oncol. Clin. North Am. (2011) pmid: 21763962", "Include": "true"}, {"number": "1", "ReferenceId": "18498744", "FullCitation": "Kaelin WG, et al. Mol. Cell (2008) pmid: 18498744", "Include": "true"}, {"number": "2", "ReferenceId": "8855222", "FullCitation": "Gnarra JR, et al. Proc. Natl. Acad. Sci. U.S.A. (1996) pmid: 8855222", "Include": "true"}, {"number": "3", "ReferenceId": "23606570", "FullCitation": "Albers J, et al. EMBO Mol Med (2013) pmid: 23606570", "Include": "true"}, {"number": "4", "ReferenceId": "22462637", "FullCitation": "Asakawa T, et al. BMC Med. Genet. (2012) pmid: 22462637", "Include": "true"}, {"number": "5", "ReferenceId": "16488999", "FullCitation": "Banks RE, et al. Cancer Res. (2006) pmid: 16488999", "Include": "true"}, {"number": "6", "ReferenceId": "21454469", "FullCitation": "Bond J, et al. Blood (2011) pmid: 21454469", "Include": "true"}, {"number": "7", "ReferenceId": "11331613", "FullCitation": "Clifford SC, et al. Hum. Mol. Genet. (2001) pmid: 11331613", "Include": "true"}, {"number": "8", "ReferenceId": "10823831", "FullCitation": "Cockman ME, et al. J. Biol. Chem. (2000) pmid: 10823831", "Include": "true"}, {"number": "9", "ReferenceId": "14556007", "FullCitation": "Corn PG, et al. Nat. Genet. (2003) pmid: 14556007", "Include": "true"}, {"number": "10", "ReferenceId": "22799452", "FullCitation": "Dandanell M, et al. BMC Med. Genet. (2012) pmid: 22799452", "Include": "true"}, {"number": "11", "ReferenceId": "10635329", "FullCitation": "Feldman DE, et al. Mol. Cell (1999) pmid: 10635329", "Include": "true"}, {"number": "12", "ReferenceId": "14636579", "FullCitation": "Feldman DE, et al. Mol. Cell (2003) pmid: 14636579", "Include": "true"}, {"number": "13", "ReferenceId": "11865071", "FullCitation": "Hansen WJ, et al. Mol. Cell. Biol. (2002) pmid: 11865071", "Include": "true"}, {"number": "14", "ReferenceId": "11331612", "FullCitation": "Hoffman MA, et al. Hum. Mol. Genet. (2001) pmid: 11331612", "Include": "true"}, {"number": "15", "ReferenceId": "17967880", "FullCitation": "Khacho M, et al. Mol. Cell. Biol. (2008) pmid: 17967880", "Include": "true"}, {"number": "16", "ReferenceId": "7660130", "FullCitation": "Kibel A, et al. Science (1995) pmid: 7660130", "Include": "true"}, {"number": "17", "ReferenceId": "16261165", "FullCitation": "Knauth K, et al. Oncogene (2006) pmid: 16261165", "Include": "true"}, {"number": "18", "ReferenceId": "14691445", "FullCitation": "Lewis MD, et al. Oncogene (2004) pmid: 14691445", "Include": "true"}, {"number": "19", "ReferenceId": "11739384", "FullCitation": "Li Z, et al. J. Biol. Chem. (2002) pmid: 11739384", "Include": "true"}, {"number": "20", "ReferenceId": "12056827", "FullCitation": "Li Z, et al. Biochem. Biophys. Res. Commun. (2002) pmid: 12056827", "Include": "true"}, {"number": "21", "ReferenceId": "19798438", "FullCitation": "Liu J, et al. PLoS Comput. Biol. (2009) pmid: 19798438", "Include": "true"}, {"number": "22", "ReferenceId": "23298237", "FullCitation": "Losonczy G, et al. BMC Med. Genet. (2013) pmid: 23298237", "Include": "true"}, {"number": "23", "ReferenceId": "8730290", "FullCitation": "Maher ER, et al. J. Med. Genet. (1996) pmid: 8730290", "Include": "true"}, {"number": "24", "ReferenceId": "15935760", "FullCitation": "McClellan AJ, et al. Cell (2005) pmid: 15935760", "Include": "true"}, {"number": "25", "ReferenceId": "19073890", "FullCitation": "Metzger MB, et al. Mol. Biol. Cell (2009) pmid: 19073890", "Include": "true"}, {"number": "26", "ReferenceId": "15611064", "FullCitation": "Miller F, et al. J. Biol. Chem. (2005) pmid: 15611064", "Include": "true"}, {"number": "27", "ReferenceId": "22022277", "FullCitation": "Moore LE, et al. PLoS Genet. (2011) pmid: 22022277", "Include": "true"}, {"number": "28", "ReferenceId": "7563486", "FullCitation": "Neumann HP, et al. JAMA (1995) pmid: 7563486", "Include": "true"}, {"number": "29", "ReferenceId": "10587522", "FullCitation": "Ohh M, et al. J. Clin. Invest. (1999) pmid: 10587522", "Include": "true"}, {"number": "30", "ReferenceId": "10878807", "FullCitation": "Ohh M, et al. Nat. Cell Biol. (2000) pmid: 10878807", "Include": "true"}, {"number": "31", "ReferenceId": "9829912", "FullCitation": "Olschwang S, et al. Hum. Mutat. (1998) pmid: 9829912", "Include": "true"}, {"number": "32", "ReferenceId": "18416845", "FullCitation": "Patocs A, et al. BMC Med. Genet. (2008) pmid: 18416845", "Include": "true"}, {"number": "33", "ReferenceId": "21715564", "FullCitation": "Rechsteiner MP, et al. Cancer Res. (2011) pmid: 21715564", "Include": "true"}, {"number": "34", "ReferenceId": "14987375", "FullCitation": "Expert Rev Mol Med (2001) pmid: 14987375", "Include": "true"}, {"number": "35", "ReferenceId": "8772572", "FullCitation": "Ritter MM, et al. J. Clin. Endocrinol. Metab. (1996) pmid: 8772572", "Include": "true"}, {"number": "36", "ReferenceId": "10900011", "FullCitation": "Schoenfeld AR, et al. Proc. Natl. Acad. Sci. U.S.A. (2000) pmid: 10900011", "Include": "true"}, {"number": "37", "ReferenceId": "23840444", "FullCitation": "Shmueli MD, et al. PLoS ONE (2013) pmid: 23840444", "Include": "true"}, {"number": "38", "ReferenceId": "21362373", "FullCitation": "Siu WK, et al. Chin. Med. J. (2011) pmid: 21362373", "Include": "true"}, {"number": "39", "ReferenceId": "12414898", "FullCitation": "Weirich G, et al. J. Clin. Endocrinol. Metab. (2002) pmid: 12414898", "Include": "true"}, {"number": "40", "ReferenceId": "8956040", "FullCitation": "Zbar B, et al. Hum. Mutat. (1996) pmid: 8956040", "Include": "true"}, {"number": "41", "ReferenceId": "14973063", "FullCitation": "Zhou MI, et al. Cancer Res. (2004) pmid: 14973063", "Include": "true"}, {"number": "42", "ReferenceId": "32234874", "FullCitation": "Shukuya T, et al. Anticancer Res (2020) pmid: 32234874", "Include": "true"}, {"number": "43", "ReferenceId": "32513235", "FullCitation": "Sun J, et al. J Exp Clin Cancer Res (2020) pmid: 32513235", "Include": "true"}, {"number": "44", "ReferenceId": "15316311", "FullCitation": "Bruder E, et al. Am. J. Surg. Pathol. (2004) pmid: 15316311", "Include": "true"}, {"number": "45", "ReferenceId": "15217927", "FullCitation": "Dulaimi E, et al. Clin. Cancer Res. (2004) pmid: 15217927", "Include": "true"}, {"number": "46", "ReferenceId": "9156283", "FullCitation": "Cancer Metastasis Rev. (1997) pmid: 9156283", "Include": "true"}, {"number": "47", "ReferenceId": "24487277", "FullCitation": "Gerlinger M, et al. Nat. Genet. (2014) pmid: 24487277", "Include": "true"}, {"number": "48", "ReferenceId": "25124064", "FullCitation": "Sankin A, et al. Cancer Med (2014) pmid: 25124064", "Include": "true"}, {"number": "49", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "50", "ReferenceId": "19216840", "FullCitation": "Cowey CL, et al. Curr Oncol Rep (2009) pmid: 19216840", "Include": "true"}, {"number": "51", "ReferenceId": "19017755", "FullCitation": "Jimenez C, et al. J. Clin. Endocrinol. Metab. (2009) pmid: 19017755", "Include": "true"}, {"number": "52", "ReferenceId": "24454008", "FullCitation": "Kim HC, et al. Cancer Res Treat (2013) pmid: 24454008", "Include": "true"}, {"number": "53", "ReferenceId": "26881543", "FullCitation": "J Cancer Res Ther () pmid: 26881543", "Include": "true"}, {"number": "54", "ReferenceId": "26812297", "FullCitation": "Babinska A, et al. Neuro Endocrinol. Lett. (2015) pmid: 26812297", "Include": "true"}, {"number": "55", "ReferenceId": "26984080", "FullCitation": "Kobayashi A, et al. Intern. Med. (2016) pmid: 26984080", "Include": "true"}, {"number": "56", "ReferenceId": "22105611", "FullCitation": "Jonasch E, et al. Ann. Oncol. (2011) pmid: 22105611", "Include": "true"}, {"number": "57", "ReferenceId": "25391617", "FullCitation": "Roma A, et al. Fam. Cancer (2015) pmid: 25391617", "Include": "true"}, {"number": "58", "ReferenceId": "16827904", "FullCitation": "Rini BI, et al. BJU Int. (2006) pmid: 16827904", "Include": "true"}, {"number": "59", "ReferenceId": "18635227", "FullCitation": "Choueiri TK, et al. J. Urol. (2008) pmid: 18635227", "Include": "true"}, {"number": "60", "ReferenceId": "25100134", "FullCitation": "Motzer RJ, et al. Cancer Chemother. Pharmacol. (2014) pmid: 25100134", "Include": "true"}, {"number": "61", "ReferenceId": "17956710", "FullCitation": "Cho D, et al. Clin Genitourin Cancer (2007) pmid: 17956710", "Include": "true"}, {"number": "62", "ReferenceId": "23881929", "FullCitation": "Choueiri TK, et al. Clin. Cancer Res. (2013) pmid: 23881929", "Include": "true"}, {"number": "63", "ReferenceId": "34818478", "FullCitation": "Jonasch E, et al. N Engl J Med (2021) pmid: 34818478", "Include": "true"}, {"number": "64", "ReferenceId": "30788497", "FullCitation": "Escudier B, et al. Ann Oncol (2019) pmid: 30788497", "Include": "true"}, {"number": "65", "ReferenceId": "26935559", "FullCitation": "Moch H, et al. Eur Urol (2016) pmid: 26935559", "Include": "true"}, {"number": "66", "ReferenceId": "21386872", "FullCitation": "Maher ER, et al. Eur. J. Hum. Genet. (2011) pmid: 21386872", "Include": "true"}, {"number": "67", "ReferenceId": "24138046", "FullCitation": "Haddad NM, et al. Semin Ophthalmol () pmid: 24138046", "Include": "true"}, {"number": "68", "ReferenceId": "22659535", "FullCitation": "Richard S, et al. Semin. Cancer Biol. (2013) pmid: 22659535", "Include": "true"}, {"number": "69", "ReferenceId": "11780067", "FullCitation": "Lemon B, et al. Nature () pmid: 11780067", "Include": "true"}, {"number": "70", "ReferenceId": "21248752", "FullCitation": "Varela I, et al. Nature (2011) pmid: 21248752", "Include": "true"}, {"number": "71", "ReferenceId": "24185509", "FullCitation": "Jiao Y, et al. Nat. Genet. (2013) pmid: 24185509", "Include": "true"}, {"number": "72", "ReferenceId": "18339845", "FullCitation": "Xia W, et al. Cancer Res. (2008) pmid: 18339845", "Include": "true"}, {"number": "73", "ReferenceId": "28921948", "FullCitation": "Hopson S, et al. ACS Chem. Biol. (2017) pmid: 28921948", "Include": "true"}, {"number": "74", "ReferenceId": "28053089", "FullCitation": "Porter EG, et al. J. Biol. Chem. (2017) pmid: 28053089", "Include": "true"}, {"number": "75", "ReferenceId": "26117423", "FullCitation": "Niimi A, et al. Mutat. Res. (2015) pmid: 26117423", "Include": "true"}, {"number": "76", "ReferenceId": "24613357", "FullCitation": "Brownlee PM, et al. Cell Rep (2014) pmid: 24613357", "Include": "true"}, {"number": "77", "ReferenceId": "25066234", "FullCitation": "Kakarougkas A, et al. Mol. Cell (2014) pmid: 25066234", "Include": "true"}, {"number": "78", "ReferenceId": "28082722", "FullCitation": "Gao W, et al. Proc. Natl. Acad. Sci. U.S.A. (2017) pmid: 28082722", "Include": "true"}, {"number": "79", "ReferenceId": "23792563", "FullCitation": "Nature (2013) pmid: 23792563", "Include": "true"}, {"number": "80", "ReferenceId": "24817979", "FullCitation": "Rao Q, et al. Int J Clin Exp Pathol (2014) pmid: 24817979", "Include": "true"}, {"number": "81", "ReferenceId": "24053427", "FullCitation": "da Costa WH, et al. BJU Int. (2014) pmid: 24053427", "Include": "true"}, {"number": "82", "ReferenceId": "22949125", "FullCitation": "Paw\u0142owski R, et al. Int. J. Cancer (2013) pmid: 22949125", "Include": "true"}, {"number": "83", "ReferenceId": "23036577", "FullCitation": "Hakimi AA, et al. Eur. Urol. (2013) pmid: 23036577", "Include": "true"}, {"number": "84", "ReferenceId": "23620406", "FullCitation": "Hakimi AA, et al. Clin. Cancer Res. (2013) pmid: 23620406", "Include": "true"}, {"number": "85", "ReferenceId": "22683710", "FullCitation": "Pe\u00f1a_Llopis S, et al. Nat. Genet. (2012) pmid: 22683710", "Include": "true"}, {"number": "86", "ReferenceId": "23333114", "FullCitation": "Kapur P, et al. Lancet Oncol. (2013) pmid: 23333114", "Include": "true"}, {"number": "87", "ReferenceId": "31486842", "FullCitation": "Braun DA, et al. JAMA Oncol (2019) pmid: 31486842", "Include": "true"}, {"number": "88", "ReferenceId": "32472114", "FullCitation": "Braun DA, et al. Nat Med (2020) pmid: 32472114", "Include": "true"}, {"number": "89", "ReferenceId": "29301960", "FullCitation": "Miao D, et al. Science (2018) pmid: 29301960", "Include": "true"}, {"number": "90", "ReferenceId": "32661119", "FullCitation": "Dizman N, et al. J Immunother Cancer (2020) pmid: 32661119", "Include": "true"}, {"number": "91", "ReferenceId": "29867230", "FullCitation": "McDermott DF, et al. Nat. Med. (2018) pmid: 29867230", "Include": "true"}, {"number": "92", "ReferenceId": "32358509", "FullCitation": "Liu XD, et al. Nat Commun (2020) pmid: 32358509", "Include": "true"}, {"number": "93", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "94", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "95", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "96", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "97", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "98", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "99", "ReferenceId": "22378480", "FullCitation": "Stoehr C, et al. Pathobiology (2012) pmid: 22378480", "Include": "true"}, {"number": "100", "ReferenceId": "33775530", "FullCitation": "Bratslavsky G, et al. Urol Oncol (2021) pmid: 33775530", "Include": "true"}, {"number": "101", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "102", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "103", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "104", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "105", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "106", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "107", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "108", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "109", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "110", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "111", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "112", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "113", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "114", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "115", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "116", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "117", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "118", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "119", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "120", "ReferenceId": "28592388", "FullCitation": "Pal SK, et al. Eur. Urol. (2018) pmid: 28592388", "Include": "true"}, {"number": "121", "ReferenceId": "23770567", "FullCitation": "Lawrence MS, et al. Nature (2013) pmid: 23770567", "Include": "true"}, {"number": "122", "ReferenceId": "23945592", "FullCitation": "Alexandrov LB, et al. Nature (2013) pmid: 23945592", "Include": "true"}, {"number": "123", "ReferenceId": "31930049", "FullCitation": "Zhang C, et al. Ann Transl Med (2019) pmid: 31930049", "Include": "true"}, {"number": "124", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "125", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "126", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "127", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "128", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "129", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "130", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "131", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "132", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "133", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "134", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "135", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "136", "ReferenceId": "32673417", "FullCitation": "Motzer RJ, et al. Cancer (2020) pmid: 32673417", "Include": "true"}, {"number": "137", "ReferenceId": "26406148", "FullCitation": "Motzer RJ, et al. N. Engl. J. Med. (2015) pmid: 26406148", "Include": "true"}, {"number": "138", "ReferenceId": "32641261", "FullCitation": "McFarlane JJ, et al. Clin Genitourin Cancer (2020) pmid: 32641261", "Include": "true"}, {"number": "139", "ReferenceId": "32718906", "FullCitation": "Vogelzang NJ, et al. Clin Genitourin Cancer (2020) pmid: 32718906", "Include": "true"}, {"number": "140", "ReferenceId": "35688173", "FullCitation": "Motzer RJ, et al. Lancet Oncol (2022) pmid: 35688173", "Include": "true"}, {"number": "141", "ReferenceId": "33657295", "FullCitation": "Choueiri TK, et al. N Engl J Med (2021) pmid: 33657295", "Include": "true"}, {"number": "142", "ReferenceId": "35390339", "FullCitation": "Vano YA, et al. Lancet Oncol (2022) pmid: 35390339", "Include": "true"}, {"number": "143", "ReferenceId": "30348216", "FullCitation": "Amin A, et al. J Immunother Cancer (2018) pmid: 30348216", "Include": "true"}, {"number": "144", "ReferenceId": "32439653", "FullCitation": "Diab A, et al. Cancer Discov (2020) pmid: 32439653", "Include": "true"}, {"number": "145", "ReferenceId": "29863979", "FullCitation": "Migden MR, et al. N. Engl. J. Med. (2018) pmid: 29863979", "Include": "true"}, {"number": "146", "ReferenceId": "33888901", "FullCitation": "Choueiri TK, et al. Nat Med (2021) pmid: 33888901", "Include": "true"}, {"number": "147", "ReferenceId": "33529051", "FullCitation": "McDermott DF, et al. J Clin Oncol (2021) pmid: 33529051", "Include": "true"}, {"number": "148", "ReferenceId": "33529058", "FullCitation": "McDermott DF, et al. J Clin Oncol (2021) pmid: 33529058", "Include": "true"}, {"number": "149", "ReferenceId": "34407342", "FullCitation": "Choueiri TK, et al. N Engl J Med (2021) pmid: 34407342", "Include": "true"}, {"number": "150", "ReferenceId": "33616314", "FullCitation": "Motzer R, et al. N Engl J Med (2021) pmid: 33616314", "Include": "true"}, {"number": "151", "ReferenceId": "33284113", "FullCitation": "Powles T, et al. Lancet Oncol (2020) pmid: 33284113", "Include": "true"}, {"number": "152", "ReferenceId": "30779529", "FullCitation": "Rini BI, et al. N. Engl. J. Med. (2019) pmid: 30779529", "Include": "true"}, {"number": "153", "ReferenceId": "34143969", "FullCitation": "Lee CH, et al. Lancet Oncol (2021) pmid: 34143969", "Include": "true"}, {"number": "154", "ReferenceId": "34006498", "FullCitation": "Chowdhury S, et al. Clin Genitourin Cancer (2021) pmid: 34006498", "Include": "true"}, {"number": "155", "ReferenceId": "29358500", "FullCitation": "Atkins MB, et al. Clin. Cancer Res. (2018) pmid: 29358500", "Include": "true"}, {"number": "156", "ReferenceId": "33709428", "FullCitation": "Tannir NM, et al. Int J Cancer (2021) pmid: 33709428", "Include": "true"}, {"number": "157", "ReferenceId": "31563517", "FullCitation": "Naing A, et al. Lancet Oncol (2019) pmid: 31563517", "Include": "true"}, {"number": "158", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_12_19 15:23:44", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "934x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "KIDNEY", "disease_ontology": "Kidney renal cell carcinoma (NOS)", "flowcell_analysis": "2000026225", "gender": "male", "pathology_diagnosis": "Renal Cell Carcinoma", "percent_tumor_nuclei": "40", "pipeline_version": "v3.17.0", "purity_assessment": "31.2", "specimen": "ORD_1521384_01*US1456453.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1521384_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Kidney", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "948.99", "name": "SQ_US1456453.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4756", "cds_effect": "1664C>T", "depth": "965", "equivocal": "false", "functional_effect": "missense", "gene": "TET2", "percent_reads": "47.56", "position": "chr4:106156763", "protein_effect": "P555L", "status": "unknown", "strand": "+", "transcript": "NM_001127208", "dna_evidence": {"sample": "SQ_US1456453.01_1"}}, {"allele_fraction": "0.4683", "cds_effect": "6639C>A", "depth": "758", "equivocal": "false", "functional_effect": "missense", "gene": "ROS1", "percent_reads": "46.83", "position": "chr6:117622231", "protein_effect": "D2213E", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1456453.01_1"}}, {"allele_fraction": "0.1239", "cds_effect": "170C>T", "depth": "452", "equivocal": "false", "functional_effect": "missense", "gene": "SOCS1", "percent_reads": "12.39", "position": "chr16:11349166", "protein_effect": "T57I", "status": "unknown", "strand": "_", "transcript": "NM_003745", "dna_evidence": {"sample": "SQ_US1456453.01_1"}}, {"allele_fraction": "0.4891", "cds_effect": "5487G>T", "depth": "959", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA2", "percent_reads": "48.91", "position": "chr13:32913979", "protein_effect": "L1829F", "status": "unknown", "strand": "+", "transcript": "NM_000059", "dna_evidence": {"sample": "SQ_US1456453.01_1"}}, {"allele_fraction": "0.1329", "cds_effect": "192_195delCTCG", "depth": "715", "equivocal": "false", "functional_effect": "frameshift", "gene": "VHL", "percent_reads": "13.29", "position": "chr3:10183722", "protein_effect": "S65fs*1", "status": "likely", "strand": "+", "transcript": "NM_000551", "dna_evidence": {"sample": "SQ_US1456453.01_1"}}, {"allele_fraction": "0.551", "cds_effect": "1979G>A", "depth": "1029", "equivocal": "false", "functional_effect": "missense", "gene": "IKBKE", "percent_reads": "55.1", "position": "chr1:206666645", "protein_effect": "G660E", "status": "unknown", "strand": "+", "transcript": "NM_014002", "dna_evidence": {"sample": "SQ_US1456453.01_1"}}, {"allele_fraction": "0.158", "cds_effect": "4090G>T", "depth": "766", "equivocal": "false", "functional_effect": "nonsense", "gene": "PBRM1", "percent_reads": "15.8", "position": "chr3:52595825", "protein_effect": "E1364*", "status": "likely", "strand": "_", "transcript": "NM_018313", "dna_evidence": {"sample": "SQ_US1456453.01_1"}}, {"allele_fraction": "0.4199", "cds_effect": "2060C>T", "depth": "924", "equivocal": "false", "functional_effect": "missense", "gene": "CARD11", "percent_reads": "41.99", "position": "chr7:2962848", "protein_effect": "A687V", "status": "unknown", "strand": "_", "transcript": "NM_032415", "dna_evidence": {"sample": "SQ_US1456453.01_1"}}, {"allele_fraction": "0.5023", "cds_effect": "514A>C", "depth": "862", "equivocal": "false", "functional_effect": "missense", "gene": "MYC", "percent_reads": "50.23", "position": "chr8:128750977", "protein_effect": "K172Q", "status": "unknown", "strand": "+", "transcript": "NM_002467", "dna_evidence": {"sample": "SQ_US1456453.01_1"}}, {"allele_fraction": "0.3853", "cds_effect": "2009T>G", "depth": "802", "equivocal": "false", "functional_effect": "missense", "gene": "MST1R", "percent_reads": "38.53", "position": "chr3:49934990", "protein_effect": "V670G", "status": "unknown", "strand": "_", "transcript": "NM_002447", "dna_evidence": {"sample": "SQ_US1456453.01_1"}}, {"allele_fraction": "0.4565", "cds_effect": "4058A>C", "depth": "896", "equivocal": "false", "functional_effect": "missense", "gene": "ROS1", "percent_reads": "45.65", "position": "chr6:117677875", "protein_effect": "Y1353S", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1456453.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.21", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}